Skip to main content
SpringerLink
Log in

A natural history study of late onset spinal muscular atrophy types 3b and 4

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Background

Spinal muscular atrophy (SMA) is caused by a homozygous deletion of the survival motor neuron (SMN)1 gene. The nearly identical SMN2 gene plays a disease modifying role. SMA is classified into four different subtypes based on age of onset and clinical course (SMA types 1–4). The natural history of early onset SMA types 1–3a has been studied extensively. Late onset SMA is rare and disease course has not been studied in detail.

Objective

To perform a prospective study on the clinical course and the correlation with SMN2 copy numbers of late onset SMA.

Methods

Patients fulfilling the diagnostic criteria for late onset SMA (types 3b and 4) were included in the study. At inclusion and follow-up, muscle strength, respiratory function, functional status and quality of life were assessed. SMN2 copy number was determined in all patients.

Results

Twelve patients were identified and included. Six patients were siblings from one family, two patients were brothers from a second family and four patients were sporadic cases. All patients carried four copies of the SMN2 gene. Median age of disease onset was 22.2 years (10–37). Age of disease onset in patients from family one was lower as compared to the other patients. None of the outcome measures changed after a follow-up of 2.5 years. Five patients reported an increase in fatigue and muscle weakness. None of the patients showed symptoms of respiratory insufficiency.

Conclusions

This study indicates that late onset SMA is not characterized by disease progression and that alternative or surrogate disease markers are required for the design of future trials. This study confirms the finding that SMN2 copy number is a SMA disease course modifier.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I–II Study Group. Arch Neurol 53:141–147

  2. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F, Moscato U, Bertini E, Mercuri E, Neri G (2005) Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 13:256–259

    Article  PubMed  CAS  Google Scholar 

  3. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12:2481–2489

    Article  PubMed  CAS  Google Scholar 

  4. Brichta L, Holker I, Haug K, Klockgether T, Wirth B (2006) In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 59:970–975

    Article  PubMed  CAS  Google Scholar 

  5. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ (1981) Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 4:186–197

    Article  PubMed  CAS  Google Scholar 

  6. Brooks D, Solway S, Gibbons WJ (2003) ATS statement on six-minute walk test. Am J Respir Crit Care Med 167:1287

    PubMed  Google Scholar 

  7. Chung BH, Wong VC, Ip P (2004) Spinal muscular atrophy: survival pattern and functional status. Pediatrics 114:548–553

    Article  Google Scholar 

  8. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, Tesi- Rocha C, Gorni K, Pasquali L, Patel KM, McCarter R, Huang J, Mayhew T, Bertorini T, Carlo J, Connolly AM, Clemens PR, Goemans N, Iannaccone ST, Igarashi M, Nevo Y, Pestronk A, Subramony SH, Vedanarayanan VV, Wessel H (2005) CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy Ann Neurol 58:151–155

    Article  PubMed  CAS  Google Scholar 

  9. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70:358–368

    Article  PubMed  CAS  Google Scholar 

  10. Gennarelli M, Lucarelli M, Capon F, Pizzuti A, Merlini L, Angelini C, Novelli G, Dallapiccola B (1995) Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun 213:342–348

    Article  PubMed  CAS  Google Scholar 

  11. Great Lake ALS Study Group (2003) A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis Neurology 61:1503–1507

    Google Scholar 

  12. Kaufmann P, Muntoni F (2007) Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design. Neuromuscul Disord 17:499–505

    Article  PubMed  CAS  Google Scholar 

  13. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–165

    Article  PubMed  CAS  Google Scholar 

  14. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR, Prior TW, Burghes AH (1997) Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 60:1411–1422

    Article  PubMed  CAS  Google Scholar 

  15. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD (1994) The MOS 36- item Short-Form Health Survey (SF- 36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups Med Care 32:40–66

    Article  PubMed  CAS  Google Scholar 

  16. Munsat TL, Davies KE (1992) International SMA consortium meeting. (26–28 June 1992, Bonn, Germany) Neuromuscul Disord 2:423–428

    Article  PubMed  CAS  Google Scholar 

  17. O’hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, Riley S, Sanborn E, Irvine C, Martens WB, Annis C, Tawil R, Oskoui M, Darras BT, Finkel RS, De V (2007) An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 17:693–697

    Article  PubMed  Google Scholar 

  18. Rudnik-Schoneborn S, Hausmanowa- Petrusewicz I, Borkowska J, Zerres K (2001) The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 45:174–181

    Article  PubMed  CAS  Google Scholar 

  19. Russman BS, Buncher CR, White M, Samaha FJ, Iannaccone ST (1996) Function changes in spinal muscular atrophy II and III. The DCN/SMA Group. Neurology 47:973–976

    PubMed  CAS  Google Scholar 

  20. Sumner CJ (2006) Therapeutics development for spinal muscular atrophy. NeuroRx 3:235–245

    Article  PubMed  CAS  Google Scholar 

  21. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovert DD, Schussler K, Chen X, Jarecki J, Burghes AH, Taylor JP, Fischbeck KH (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54:647–654

    Article  PubMed  CAS  Google Scholar 

  22. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB (2005) Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 57:704–712

    Article  PubMed  CAS  Google Scholar 

  23. Taylor JE, Thomas NH, Lewis CM, Abbs SJ, Rodrigues NR, Davies KE, Mathew CG (1998) Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy. Eur J Hum Genet 6:467–474

    Article  PubMed  CAS  Google Scholar 

  24. Tomaszewicz K, Kang P, Wu BL (2005) Detection of homozygous and heterozygous SMN deletions of spinal muscular atrophy in a single assay with multiplex ligation-dependent probe amplification Beijing Da Xue Xue Bao 37:55–57

    Google Scholar 

  25. Weihl CC, Connolly AM, Pestronk A (2006) Valproate may improve strength and function in patients with type III/ IV spinal muscle atrophy. Neurology 67:500–501

    Article  PubMed  CAS  Google Scholar 

  26. Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, Heller R (2006) Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number Hum Genet 119:422–428

    Article  PubMed  CAS  Google Scholar 

  27. Zerres K, Rudnik-Schoneborn S (1995) Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 52:518–523

    PubMed  CAS  Google Scholar 

  28. Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I (1997) A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients J Neurol Sci 146:67–72

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, HP G 02.320, 85500, 3508, GA Utrecht, The Netherlands

    S. Piepers MD, L. H. van den Berg MD, PhD, F. Brugman MD, W.-L. van der Pol MD, PhD & J. H. J. Wokke MD, PhD

  2. Dept. of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

    H. Scheffer PhD & M. Ruiterkamp-Versteeg

  3. Dept. of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands

    B. G. van Engelen MD, PhD

  4. Dept. of Neurology, University Medical Center, Maastricht, The Netherlands

    C. G. Faber MD, PhD

  5. Dept. of Neurology, Academic Medical Center, Amsterdam, The Netherlands

    M. de Visser MD, PhD

Authors
  1. S. Piepers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. H. van den Berg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Brugman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Scheffer PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Ruiterkamp-Versteeg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. G. van Engelen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. G. Faber MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. de Visser MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W.-L. van der Pol MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. H. J. Wokke MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Piepers MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piepers, S., van den Berg, L.H., Brugman, F. et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol 255, 1400–1404 (2008). https://doi.org/10.1007/s00415-008-0929-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-0929-0

Key words

Search

Navigation